For example, one of the personalized methods of PCa risk calculation is to include clinical data of patients, consisting of PSA levels, and PCa Antigen 3 (PCa3) and TMPRSS2-ERG (T2:ERG) expression [105]. This evidence concerns the gene KLK3 and posterior cortical atrophy.